Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Pharma-Bio Serv (PBSV) Cash from Financing Activities (2016 - 2026)

Pharma-Bio Serv (PBSV) has disclosed Cash from Financing Activities for 16 consecutive years, with -$9202.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities changed N/A year-over-year to -$9202.0, compared with a TTM value of -$1.8 million through Oct 2025, down 1.03%, and an annual FY2025 reading of -$1.8 million, down 1.03% over the prior year.
  • Cash from Financing Activities was -$9202.0 for Q4 2025 at Pharma-Bio Serv, down from -$5004.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $41113.0 in Q4 2021 and bottomed at -$1.8 million in Q2 2021.
  • Average Cash from Financing Activities over 5 years is -$657808.8, with a median of -$8197.5 recorded in 2024.
  • The sharpest move saw Cash from Financing Activities surged 400.34% in 2021, then tumbled 62248.3% in 2022.
  • Year by year, Cash from Financing Activities stood at $41113.0 in 2021, then tumbled by 105.79% to -$2379.0 in 2022, then skyrocketed by 66.71% to -$792.0 in 2023, then tumbled by 120.58% to -$1747.0 in 2024, then tumbled by 426.73% to -$9202.0 in 2025.
  • Business Quant data shows Cash from Financing Activities for PBSV at -$9202.0 in Q4 2025, -$5004.0 in Q3 2025, and -$1.7 million in Q2 2025.